<DOC>
	<DOC>NCT02823808</DOC>
	<brief_summary>All subjects will be randomized as Alo/Pio combo group (intervention) or Glim/Met combo group (control) after intensive COAD treatment based on identical protocol. - All subject will be managed with once daily, fixed dose, single tablet treatment based on the study protocol, and followed-up for 104 weeks. - Any group of subjects who fail to reach glycemic target with single tablet treatment, subject will be treated with rescue medication and stopped regular observation.</brief_summary>
	<brief_title>Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patients Patient who had been diagnosed within the previous 12 months with HbA1c levels of 8.012.0%, did not have a medical history related to diabetes, and did not display proliferative retinopathy The use of weightlowering drugs, any investigational bloodglucose or lipidlowering agent (other than statins or ezetimibe) within the past 3 months Previous treatment with systemic corticosteroids or a change in dosage of thyroid hormones in the previous 6 weeks The use of insulin within the 3 months prior to screening Others</criteria>
	<gender>All</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>